Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith the Annual Secretarial Compliance Report for the Financial Year 2025-2026.
Regulatory Filings Classification · 87% confidence The document is an Annual Secretarial Compliance Report filed under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a certification/attestation by the Company Secretary and Practicing Company Secretary on statutory and regulatory compliance (not a full financial statement or governance charter). It does not present financial results or detailed investor presentation material. Under the “Certification Rule,” documents that are officer certifications or regulatory compliance attestations are classified as Regulatory Filings (RNS).
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges (BSE and NSE) about the schedule of upcoming analyst and institutional investor meetings. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance announcement. The content is purely informational about meeting dates and venues, with no financial data, report content, or detailed analysis. The document length is short (2134 characters), and it does not contain any financial statements or detailed report material. It is not a report itself but an announcement related to investor relations activities. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-19 English
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 87% confidence The document is an exchange filing under SEBI LODR, providing a schedule of upcoming analyst/ institutional investor meetings. It contains no substantive financial data or presentation materials and is simply a regulatory disclosure notice. This best fits the “Regulatory Filings” fallback category (RNS).
2026-05-19 English
General Updates
Regulatory Filings Classification · 89% confidence The document is a disclosure made under Regulation 30 of SEBI Listing Obligations, notifying the successful closure of a US FDA inspection at a manufacturing facility. It is a regulatory announcement/compliance filing to stock exchanges, not a financial report, management commentary, or other specified category. This fits the ‘Regulatory Filings’ fallback category.
2026-05-18 English
Please refer attached file
Regulatory Filings Classification · 90% confidence The document is a regulatory disclosure letter under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 to the stock exchanges, informing the market about the successful closure of a US FDA inspection and issuance of an Establishment Inspection Report. It does not contain financial statements, vote results, management changes, or other specific report content, nor is it announcing publication of a financial report. This fits the fallback category for general regulatory announcements: RNS.
2026-05-18 English
General Updates
Regulatory Filings Classification · 85% confidence The document is a standard stock exchange disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, informing about the outcome of a US FDA GMP inspection. It does not include financial statements, management discussion, or voting results. It is a regulatory compliance announcement rather than a substantive report or filing like an Annual Report or Interim Report. Therefore, it falls under Regulatory Filings.
2026-05-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.